Story · Medicine & Biotech
FDA Adds Another Player in ALK-Positive Lung Cancer
5 outlets · first reported by FDA Drug Safety / Drugs feed on · latest · 27 hours of coverage
(MedPage Today) -- The FDA granted accelerated approval to the third-generation ALK inhibitor neladalkib (Nelkarmi) for previously treated advanced ALK-positive non-small cell lung cancer (NSCLC), making it the seventh approved agent in a crowded... (MedPage Today)
Coverage, in order
-
FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer
On November 16, 2026, the FDA approved giredestrant (Wilserdly, Genentech, Inc.), an oral estrogen receptor antagonist, in combination with everolimus for the treatment of adults with certain types of metastatic breast cancer. Learn more.
-
FDA Approves Giredestrant Plus Everolimus for ESR1 -Mutant Advanced Breast Cancer
On November 16, the oral estrogen receptor antagonist giredestrant (Wilserdly), in combination with everolimus, was approved for the treatment of adults with estrogen receptor (ER)-positive, HER2-negative, ESR1 -mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized…
-
FDA Grants Accelerated Approval to Neladalkib for ALK -Positive NSCLC
Today, neladalkib (Nelkarmi), a kinase inhibitor, was granted accelerated approval for adults with previously treated, locally advanced or metastatic ALK -positive non–small cell lung cancer (NSCLC).
-
FDA Approves Giredestrant Plus Everolimus for Advanced Breast Cancer With ER-Positive ESR1 MutationsThe FDA has approved giredestrant plus everolimus for adults with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an ESR1 mutation detected by an FDA-authorized test. Roche
-
Wilserdly grabs FDA approval in ESR1-mutated breast cancerThe FDA approved giredestrant in combination with everolimus for adults with locally advanced or metastatic breast cancer. Giredestrant (Wilserdly, Genentech) plus everolimus received approval for treatment of estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic…
-
FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer
FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer
-
FDA Approves Giredestrant Plus Everolimus: A New Treatment Option for ESR1-Mutated Advanced Breast CancerThe US Food and Drug Administration has approved giredestrant plus everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer following prior endocrine-based treatment. The November
-
Olubukola Ayodele: New FDA Approval Expands Treatment Options for ESR1-Mutated Breast CancerOlubukola Ayodele, Co-Convenor (Co-Chair) of London Global Cancer Week, shared on LinkedIn: “On 16 November, the FDA approved giredestrant + everolimus for ESR1-mutated, ER+/HER2− advanced or metastatic breast cancer following
-
FDA Adds Another Player in ALK-Positive Lung Cancer(MedPage Today) -- The FDA granted accelerated approval to the third-generation ALK inhibitor neladalkib (Nelkarmi) for previously treated advanced ALK-positive non-small cell lung cancer (NSCLC), making it the seventh approved agent in a crowded...
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.